Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical trials without systematic review methodology
PubMed 19641280 · doi:10.3810/pgm.2009.07.2020
What was done
This narrative review examined the role and clinical trial evidence of prescription omega-3-acid ethyl esters (containing 465 mg EPA and 375 mg DHA per 1 g capsule) for managing very high triglyceride levels (≥ 500 mg/dL) alongside lifestyle modifications.
What was found
Clinical trials reviewed indicate that four 1 g capsules daily of prescription omega-3 fatty acids reduce serum triglyceride levels by up to 45% in adults with very high triglycerides, with good general tolerability. The abstract provides no other quantitative metrics or statistical values.
Why it matters
Very high triglyceride levels require prompt intervention to prevent complications; prescription omega-3 formulations offer a standardized pharmacologic option to achieve substantial triglyceride lowering.
Limits
The abstract describes a narrative review rather than a systematic review or primary trial, omitting search criteria, trial counts, participant numbers, adverse event rates, and hard cardiovascular outcome data.
Cited by
- context Lovaza contains EPA and DHA in an approximate ratio of 2:1 to 3:2.
- context Lovaza received FDA approval to lower triglycerides by about 20% specifically in patients with baseline triglyceride levels exceeding 500 mg/dL.